What does Crohn - en Colitis ulcerosa Vereniging vzw do?

Crohn - en Colitis ulcerosa Vereniging vzw is filed with the CBE under the catch-all “Verenigingen op het vlak van ziektepreventie en gezondheidsbevordering”, a code that says little about what the company actually does. Non-profit, started on 20 December 1981, 1 establishment.

What is the address of Crohn - en Colitis ulcerosa Vereniging vzw?

The registered office of Crohn - en Colitis ulcerosa Vereniging vzw is located at Groeneweg 151, 3001 Leuven.

Is Crohn - en Colitis ulcerosa Vereniging vzw still active?

Yes. According to the CBE (29 October 2026) Crohn - en Colitis ulcerosa Vereniging vzw is active, legal situation “Normale toestand”, started on 20 December 1981.

Is Crohn - en Colitis ulcerosa Vereniging vzw registered on Peppol?

Yes, Crohn - en Colitis ulcerosa Vereniging vzw is registered on the Peppol network with ID 0208:0422701650.

What is the enterprise number of Crohn - en Colitis ulcerosa Vereniging vzw?

The enterprise number of Crohn - en Colitis ulcerosa Vereniging vzw is BE0422701650.

When was Crohn - en Colitis ulcerosa Vereniging vzw founded?

Crohn - en Colitis ulcerosa Vereniging vzw was founded on 20 December 1981.

Who are the directors of Crohn - en Colitis ulcerosa Vereniging vzw?

According to the 2025 annual accounts, the directors of Crohn - en Colitis ulcerosa Vereniging vzw are: Mark De Backer, Frieda Wieme, Gemma Reynders-Broos, Mariëlle De Ridder, Kristien Amter, Colette Baisier, Kathleen Van Swalm, Ilse De Clercq.

Is Crohn - en Colitis ulcerosa Vereniging vzw a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 20 December 1981; 5 annual accounts filed, latest fiscal year 2025; 9 directors known from the annual account.

How much profit did Crohn - en Colitis ulcerosa Vereniging vzw make in 2025?

Crohn - en Colitis ulcerosa Vereniging vzw posted a profit after taxes of € 83,637 in financial year 2025.

What is the revenue of Crohn - en Colitis ulcerosa Vereniging vzw?

In its most recent annual accounts (2025), Crohn - en Colitis ulcerosa Vereniging vzw reported revenue of € 220,087.

Crohn - en Colitis ulcerosa Vereniging vzw (Non-profit)

Dossier Crohn - en Colitis ulcerosa Vereniging vzw, printed on 29 October 2026 from databakkes.be/en/0422701650/crohn-en-colitis-ulcerosa-vereniging-vzw. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Crohn - en Colitis ulcerosa Vereniging vzw from Leuven, company number BE0422701650, closed financial year 2025 with a result of € 83,637 after tax. For that financial year Crohn - en Colitis ulcerosa Vereniging vzw recorded revenue of € 220,087 and equity of € 145,436. Compared with financial year 2024, the result moved from € 8,497 to € 83,637. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 2, 2026.

What it is worth Growing

€ 145,436

▲ 135% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 83,637

▲ € 75,140 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 158,566

▲ 19% vs 2024

Cash and bank balances on the last day of the fiscal year.

People and assets in 2025

Wage cost

€ 35,429

▲ 7% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 122

▼ 96% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 8,534

▼ 48% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 63,427 Revenue 2022: € 63,427 First fiscal year in the series	-	€ 86,941 Revenue 2024: € 86,941 First fiscal year in the series	€ 220,087 Revenue 2025: € 220,087 ▲ 153% vs 2024 (€ 86,941) Favourable step	▲ 153%
Gross margin	€ 6,533 Gross margin 2022: € 6,533 First fiscal year in the series	€ -2,153 Gross margin 2023: € -2,153 ▼ € 8,686 vs 2022 (€ 6,533) Unfavourable step	€ 42,100 Gross margin 2024: € 42,100 ▲ € 44,254 vs 2023 (€ -2,153) Favourable step	€ 119,493 Gross margin 2025: € 119,493 ▲ 184% vs 2024 (€ 42,100) Favourable step	▲ 184%
Profit after taxes	€ -33,263 Profit after taxes 2022: € -33,263 First fiscal year in the series	€ -38,499 Profit after taxes 2023: € -38,499 ▼ € 5,236 vs 2022 (€ -33,263) Unfavourable step	€ 8,497 Profit after taxes 2024: € 8,497 ▲ € 46,996 vs 2023 (€ -38,499) Favourable step	€ 83,637 Profit after taxes 2025: € 83,637 ▲ € 75,140 vs 2024 (€ 8,497) Favourable step	▲ € 75,140
Equity	€ 91,801 Equity 2022: € 91,801 First fiscal year in the series	€ 53,302 Equity 2023: € 53,302 ▼ 42% vs 2022 (€ 91,801) Unfavourable step	€ 61,799 Equity 2024: € 61,799 ▲ 16% vs 2023 (€ 53,302) Favourable step	€ 145,436 Equity 2025: € 145,436 ▲ 135% vs 2024 (€ 61,799) Favourable step	▲ 135%
Total debts	€ 29,398 Total debts 2022: € 29,398 First fiscal year in the series	€ 19,017 Total debts 2023: € 19,017 ▼ 35% vs 2022 (€ 29,398) Favourable step	€ 81,663 Total debts 2024: € 81,663 ▲ € 62,647 vs 2023 (€ 19,017) Unfavourable step	€ 27,354 Total debts 2025: € 27,354 ▼ 67% vs 2024 (€ 81,663) Favourable step	▼ 67%
Cash	€ 99,183 Cash 2022: € 99,183 First fiscal year in the series	€ 64,217 Cash 2023: € 64,217 ▼ 35% vs 2022 (€ 99,183) Unfavourable step	€ 133,364 Cash 2024: € 133,364 ▲ 108% vs 2023 (€ 64,217) Favourable step	€ 158,566 Cash 2025: € 158,566 ▲ 19% vs 2024 (€ 133,364) Favourable step	▲ 19%
Retained profit	€ 91,801 Retained profit 2022: € 91,801 First fiscal year in the series	€ 53,302 Retained profit 2023: € 53,302 ▼ 42% vs 2022 (€ 91,801) Unfavourable step	€ 61,799 Retained profit 2024: € 61,799 ▲ 16% vs 2023 (€ 53,302) Favourable step	€ 145,436 Retained profit 2025: € 145,436 ▲ 135% vs 2024 (€ 61,799) Favourable step	▲ 135%
Balance sheet total	€ 121,199 Balance sheet total 2022: € 121,199 First fiscal year in the series	€ 72,319 Balance sheet total 2023: € 72,319 ▼ 40% vs 2022 (€ 121,199) Unchanged	€ 143,462 Balance sheet total 2024: € 143,462 ▲ 98% vs 2023 (€ 72,319) Unchanged	€ 172,790 Balance sheet total 2025: € 172,790 ▲ 20% vs 2024 (€ 143,462) Unchanged	▲ 20%

Key figures of Crohn - en Colitis ulcerosa Vereniging vzw, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Crohn - en Colitis ulcerosa Vereniging vzw?

What happened at Crohn - en Colitis ulcerosa Vereniging vzw in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2027 Mark De Backer stepped down as director. NBB
2027 Frieda Wieme stepped down as director. NBB
2027 Gemma Reynders-Broos stepped down as director. NBB
2027 Mariëlle De Ridder stepped down as director. NBB
2027 Kristien Amter stepped down as director. NBB
2027 Colette Baisier stepped down as director. NBB
2027 Kathleen Van Swalm stepped down as director. NBB
2027 Ilse De Clercq stepped down as director. NBB

In short

From € 33,263 loss in 2022 to € 83,637 profit in 2025.

Best year ever: 2025, with € 83,637 profit.

Original PDFs at the National Bank ↗

Management

Directors

According to the 2025 annual accounts

Mark De Backer

Director

· until 2027

Frieda Wieme

Director

· until 2027

Gemma Reynders-Broos

Director

· until 2027

Mariëlle De Ridder

Director

· until 2027

Kristien Amter

Director

· until 2027

Colette Baisier

Vice-chairman of the board

· until 2027

Kathleen Van Swalm

Director

· until 2027

Ilse De Clercq

Director

· until 2027

Lynn Debrun

Chairman of the board

· until 2027

Establishments

Establishment units

Physical locations of this company

Registered office

Groeneweg 151

3001 Leuven

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

Similes Vlaanderen

€ 26,893 revenue · 2025

Vrienden van Similes

Fonds Similes

SocA

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0422.701.650
VAT number: BE 0422.701.650
Registered office: Groeneweg 151, 3001 Leuven
Names & denominations: Crohn - en Colitis ulcerosa Vereniging vzw · CCC-vzw · Vereniging voor patiënten met een inflammatoire darmziekte (I.B.D.)
Enterprise type: Rechtspersoon
Legal form: Non-profit association
Legal situation: Normale toestand
Start date: 20 December 1981
Peppol: Active · Active since 24 Nov 2023
Activities · NACE: Verenigingen op het vlak van ziektepreventie en gezondheidsbevordering

View on CBE Public ↗ Annual accounts (NBB) ↗

Crohn - en Colitis ulcerosa Vereniging vzw

Financials

What happened to Crohn - en Colitis ulcerosa Vereniging vzw?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions